Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.
Also called NCT06689839
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 500 participants
- Sponsor
- EnCompass Technologies, Inc.
- Registry
-
NCT06689839
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia
- Registry status
- Recruiting
Technical summary
Registry record NCT06689839. Randomized; single masking; primary purpose treatment. Start 2025-09-09 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
- Acronym
- SHIELD
- Condition
- Aortic Stenosis Treated With TAVI
- Condition
- Aortic Diseases
- Intervention (Device)
- F2 Filter and Delivery System
- Intervention (Procedure)
- Transcatheter Aortic Valve Replacement (TAVR (transcatheter aortic valve replacement))
- Lead sponsor
- EnCompass Technologies, Inc.
- Collaborator
- DP Clinical, Inc.
- Collaborator
- Avania Pty Ltd
Record details
- Record id
cardio:ct-nct06689839- Content hash
103c3e27149851947f8679befcbf5d0fb29ab838231464a422b3c71c0be823df